Guardant Health reported after the close of the market on Thursday that its first quarter 2019 revenues were up 84 percent year over year.

Grail said today that it has raised $390 million in a Series D financing round, which included new investors Public Sector Pension Investment Board, Canada Pension Plan Investment Board, and two other undisclosed contributors.

The company is recalling three lots of Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) due to potential N-Nitrosodimethylamine (NDMA) contamination.

The company is recalling Tetracycline HCl Capsules USP, 250 mg and 500 mg, 100-count bottles because of failed dissolution specifications.

Arch Venture Partners, an investment company headquartered in Chicago, IL, announced on April 2, 2020 that it closed two new funds

Alnylam Pharmaceuticals, an RNA interference (RNAi) therapeutics company located in Cambridge, MA, and Blackstone Life Sciences, a private investment platform

The novel coronavirus pandemic has presented the global pharma industry with a double challenge: to develop potential treatments and preventative vaccines, and continue to meet the existing needs of healthcare providers and patients

Moderna, a clinical stage biotechnology company headquartered in Cambridge, MA, announced on April 16, 2020 that the Biomedical Advanced Research and Development Authority (BARDA)

4D pharma to Launch Phase-II Study of Biotherapeutic Product for COVID-19 Treatment

Mannitol has been shown to improve patient perceptions of tablet flavor and mouthfeel, but its use can add to tableting challenges. SPI Pharma has developed new grades of material designed to make it easier to manufacture in patient-centered formulations.

A quick look at the history of OTC dosage form development shows the importance of patient-centered innovation.

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.

Applied DNA Sciences said on Tuesday that it has partnered with Stony Brook University Hospital to validate the company's SARS-CoV-2 diagnostic.

Envisagenics announced Tuesday it has entered into a research program agreement with Johnson & Johnson's Lung Cancer Initiative (LCI.)

A group of life sciences and bioinformatics companies have banded together in the race to find treatments, vaccines, and a cure for COVID-19.